Related Experiment Video
Updated: May 20, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Hypofractionated radiotherapy in prostate cancer
Peter Vavassis1, David H A Nguyen, Jean-Paul Bahary
1Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, 5415 Boulevard de l'Assomption, Montréal, QC H1T 2M4, Canada.
Expert Review of Anticancer Therapy
|August 1, 2012
Summary
Hypofractionated radiotherapy may offer advantages for prostate cancer treatment by delivering a higher biological dose in fewer sessions. This review examines the current evidence for this approach in managing prostate cancer.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Standard prostate cancer radiotherapy involves 70-80 Gy in 2-Gy daily fractions.
- Prostate cancer cells exhibit radiobiological characteristics potentially favoring hypofractionation.
- Previous studies have explored hypofractionated treatment options.
Purpose of the Study:
- To critically review the current knowledge on hypofractionated radiotherapy for prostate cancer.
- To evaluate the theoretical and practical advantages of reduced fraction radiotherapy.
Main Methods:
- Comprehensive literature search of recent and older publications.
- Critical analysis of existing studies on prostate cancer hypofractionation.
- Synthesis of radiobiological principles and clinical outcomes.
Main Results:
- Hypofractionation allows for a higher biological effective dose per treatment.
- Reduced number of fractions may enhance treatment efficiency.
- Evidence from various studies is synthesized to assess efficacy and safety.
Conclusions:
- Hypofractionated radiotherapy presents a theoretically advantageous approach for prostate cancer.
- Further research and clinical validation are ongoing.
- This review consolidates current understanding of hypofractionation in prostate cancer management.
